|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
179,400,000 |
Market
Cap: |
199.13(M) |
Last
Volume: |
686,440 |
Avg
Vol: |
2,244,045 |
52
Week Range: |
$0.449 - $1.83 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Nektar Therapeutics is a research-based biopharmaceutical company. Co.'s research and development pipeline of investigational drugs includes potential therapies for cancer and autoimmune disease. Co.'s proprietary programs include: Immuno-oncology, which involves in developing medicines that target biological pathways which stimulate and sustain the body's immune response in order to fight cancer; and Pain, NKTR-181, a mu-opioid analgesic drug candidate patients with chronic low back pain. Co.'s NKTR-358 is an investigational drug designed to correct the underlying immune system imbalance in the body which occurs in patients with autoimmune disease.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
27,398 |
133,163 |
206,518 |
439,773 |
Total Sell Value |
$35,069 |
$211,063 |
$253,972 |
$733,404 |
Total People Sold |
3 |
5 |
5 |
9 |
Total Sell Transactions |
3 |
8 |
14 |
31 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Thomsen Jillian B. |
SVP & Chief Accounting Officer |
|
2016-03-09 |
4 |
AS |
$11.79 |
$176,850 |
D/D |
(15,000) |
5,158 |
|
- |
|
Thomsen Jillian B. |
SVP & Chief Accounting Officer |
|
2016-03-09 |
4 |
OE |
$6.65 |
$99,750 |
D/D |
15,000 |
20,158 |
|
- |
|
Gergel Ivan |
SVP & Chief Medical Officer |
|
2016-02-17 |
4 |
S |
$11.92 |
$6,628 |
D/D |
(556) |
694 |
|
- |
|
Hora Maninder |
SVP Pharma Dev & Mfg Ops |
|
2016-02-17 |
4 |
S |
$11.92 |
$11,479 |
D/D |
(963) |
5,803 |
|
- |
|
Robin Howard W |
President & CEO |
|
2016-02-17 |
4 |
S |
$11.92 |
$25,592 |
D/D |
(2,147) |
13,478 |
|
- |
|
Nicholson John |
SVP & Chief Financial Officer |
|
2016-02-17 |
4 |
S |
$11.92 |
$11,479 |
D/D |
(963) |
76,319 |
|
- |
|
Doberstein Stephen K |
SVP & Chief Scientific Officer |
|
2016-02-17 |
4 |
S |
$11.92 |
$4,649 |
D/D |
(390) |
485 |
|
- |
|
Thomsen Jillian B. |
SVP & Chief Accounting Officer |
|
2016-02-17 |
4 |
S |
$11.92 |
$8,535 |
D/D |
(716) |
5,158 |
|
- |
|
Labrucherie Gil M |
SVP & General Counsel |
|
2016-02-17 |
4 |
S |
$11.92 |
$9,858 |
D/D |
(827) |
6,590 |
|
- |
|
Gergel Ivan |
SVP & Chief Medical Officer |
|
2016-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,250 |
1,250 |
|
- |
|
Hora Maninder |
SVP Pharma Dev & Mfg Ops |
|
2016-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,166 |
6,766 |
|
- |
|
Robin Howard W |
President & CEO |
|
2016-02-16 |
4 |
OE |
$0.00 |
$1 |
D/D |
5,625 |
15,625 |
|
- |
|
Nicholson John |
SVP & Chief Financial Officer |
|
2016-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,166 |
77,282 |
|
- |
|
Doberstein Stephen K |
SVP & Chief Scientific Officer |
|
2016-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
875 |
875 |
|
- |
|
Thomsen Jillian B. |
SVP & Chief Accounting Officer |
|
2016-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,875 |
5,874 |
|
- |
|
Labrucherie Gil M |
SVP & General Counsel |
|
2016-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,166 |
7,417 |
|
- |
|
Labrucherie Gil M |
SVP & General Counsel |
|
2016-02-10 |
4 |
AS |
$11.49 |
$134,042 |
D/D |
(11,666) |
5,251 |
|
- |
|
Labrucherie Gil M |
SVP & General Counsel |
|
2016-02-10 |
4 |
OE |
$6.46 |
$75,362 |
D/D |
11,666 |
16,917 |
|
- |
|
Thomsen Jillian B. |
SVP & Chief Accounting Officer |
|
2016-02-10 |
4 |
AS |
$11.49 |
$172,350 |
D/D |
(15,000) |
3,999 |
|
- |
|
Thomsen Jillian B. |
SVP & Chief Accounting Officer |
|
2016-02-10 |
4 |
OE |
$6.65 |
$99,750 |
D/D |
15,000 |
18,999 |
|
- |
|
Robin Howard W |
President & CEO |
|
2016-02-10 |
4 |
AS |
$11.49 |
$765,992 |
D/D |
(66,666) |
10,000 |
|
- |
|
Robin Howard W |
President & CEO |
|
2016-02-10 |
4 |
OE |
$6.46 |
$430,662 |
D/D |
66,666 |
76,666 |
|
- |
|
Lingnau Lutz |
Director |
|
2016-01-20 |
4 |
AS |
$14.51 |
$217,650 |
D/D |
(15,000) |
16,450 |
|
- |
|
Lingnau Lutz |
Director |
|
2016-01-20 |
4 |
OE |
$5.15 |
$77,250 |
D/D |
15,000 |
31,450 |
|
- |
|
Thomsen Jillian B. |
SVP & Chief Accounting Officer |
|
2016-01-19 |
4 |
AS |
$14.12 |
$211,800 |
D/D |
(15,000) |
3,999 |
|
- |
|
709 Records found
|
|
Page 25 of 29 |
|
|